Psychedelic Business Intelligence was formed with the singular purpose of elevating the level of strategic business information available to participants across the emerging psychedelic industry.

By integrating qualitative insight and unique perspective from industry leaders with quantitative market intelligence across clinical services, products, M&A and investment activity, Psychedelic Business Intelligence provides decision-makers with a structured framework for evaluating opportunity, managing risk, and building durable enterprises.

This mission is delivered through two complementary platforms.The quarterly Psychedelic Business Journal provides proprietary research, market segment analysis, regulatory intelligence, executive interviews, and Excel-formatted datasets covering the psychedelic value chain — from research and development through clinical delivery and distribution channels. Each edition combines qualitative reporting with market segmentation, share, size and growth models, equipping subscribers with both context and data.

The annual Psychedelic Business Summit brings together industry participants of all types: researchers, operators, regulators, legal experts, and investors in an executive-level forum focused on disciplined commercialization and long-term industry collaboration.

Together, PBJ and the Summit create a complementary platform of independent analysis and industry collaboration and networking. Psychedelic Business Intelligence does not exist to report news on the industry — it provides strategic intelligence to strengthen the psychedelic industry's legitimacy and foundation. PBI is building a community of industry leaders and pioneers, supporting informed capital and human resource allocation, responsible commercialization, regulatory credibility, and the advancement of safe, affordable, and accessible psychedelic therapies.
‍